Major medical organizations updated the cholesterol playbook for the first time in years, with new risk tools, lower targets and earlier treatment recommendations.

Researchers have pinpointed a gene mutation associated with survival at high altitudes that could restore myelin to damaged ...

ACC/AHA guidance also gives boost to non-cholesterol tests ...

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializa ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:30 AM EDTCompany ParticipantsAmy Parison - Senior VP ...

CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the ...

Drug-resistant epilepsy affects millions worldwide, with focal cortical dysplasia (FCD) as one of the leading causes. Yet its ...

Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company’s TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global ...

Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that exceeded analyst expectations, with the gene editing company posting a loss of $0.06 per ...

Editas Medicine EDIT reported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents ...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinic ...